MetaCap

Aura Biosciences (AURA) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Solid Biosciences (SLDB) has outperformed Aura Biosciences (AURA) over the past year, gaining 33.0% versus a gain of 26.3%. Over five years, AURA leads with a -69.6% price change compared with -77.8% for SLDB. Aura Biosciences is the larger company by market cap ($715.0 million vs $697.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+26.29%SLDB+32.98%
+145%+64%-16%
Nov 21, 20251 yearNov 20, 2026
AURA-69.47%SLDB-79.06%
+5%-47%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus SLDB key metrics
MetricAURASLDB
Share price$6.87$6.25
Market cap$714.99M$697.57M
1-day change-1.58%-2.95%
YTD return+26.06%+10.82%
1-year return+26.29%+32.98%
5-year return-69.63%-77.78%
EPS (TTM)$-1.59$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-106.19M$-174.32M
52-week high$9.54$11.45
52-week low$4.73$4.65
Distance from 52-week high-27.95%-45.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+141.63%+199.36%
Average volume847.22K1.30M
Shares outstanding104.07M111.61M
Employees113121
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

AURA vs SLDB FAQ

Which is bigger, Aura Biosciences or Solid Biosciences?

Aura Biosciences (AURA) is larger, with a market capitalization of $714.99M compared with $697.57M for Solid Biosciences (SLDB).

Which stock has performed better over the past year, AURA or SLDB?

SLDB returned +32.98% over the past 12 months, compared with +26.29% for AURA (price return, excluding dividends). Past performance does not predict future results.

Are Aura Biosciences and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons